Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.
A study of nearly 700 patients found that smokers undergoing surgery for esophageal cancer experienced significantly more complications, including higher rates of pneumonia and respiratory distress, than nonsmokers—though smoking did not independently impact long-term survival.
Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.
A JAMA review revealed that only 26% of pediatric ABRS patients treated with placebo required subsequent antibiotic therapy, prompting questions about current guidelines recommending first-line antibiotic use in children with sinusitis.
Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.